Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | PLA2G4B | P0C869 | 7/20 | 0.66 |
| ▸ | LTA4H | P09960 | 2/20 | 0.64 |
| ▸ | RARB | P10826 | 3/20 | 0.62 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.61 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798961 | 1.00 | TP53 (0.68) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL5819932 | 1.00 | TP53 (0.68) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL382171 | 1.00 | TP53 (0.68) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL5820211 | 1.00 | TP53 (0.68) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL5814527 | 1.00 | TP53 (0.68) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL4801986 | 1.00 | TP53 (0.68) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL4365542 | 0.95 | LTA4H (0.63) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL4366629 | 0.95 | LTA4H (0.63) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL5816099 | 0.94 | TP53 (0.60) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL5819940 | 0.94 | TP53 (0.60) | TP53TSHRPLA2G4BLTA4HRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029513-A1 | Methods And Compositions For Generating Mixtures Of Nucleic Acid Molecules | AGILENT TECHNOLOGIES, INC. | 2010-02-04 | — | — | US | claimed |
| EP-2121719-A2 | 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS | Alios Biopharma, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| US-7576119-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | claimed |
| WO-2009086192-A1 | BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2009086201-A1 | 2-5A ANALOGS AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI- PARAS ITI C AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2008095040-A2 | 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS | ALIOS BIOPHARMA, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| US-7345163-B2 | Process for separating and deprotecting oligonucleotides | QUIATECH AB (SE) | 2008-03-18 | — | — | US | claimed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | claimed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | claimed |
| WO-2006132588-A1 | METHOD FOR THE PURIFICATION OF SYNTHETIC OLIGONUCLEOTIDES CONTAINING ONE OR SEVERAL LABELS | QUIATECH AB (SE) | 2006-12-14 | — | — | WO | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| JP-H09510206-A | — | — | 1997-10-14 | — | — | JP | claimed |
| US-5623068-A | Synthesis of DNA using substituted phenylacetyl-protected nucleotides | BECKMAN INSTRUMENTS, INC. (US) | 1997-04-22 | — | — | US | claimed |
| EP-0749436-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1996-12-27 | — | — | EP | claimed |
| US-5574146-A | Oligonucleotide synthesis with substituted aryl carboxylic acids as activators | BECKMAN INSTRUMENTS, INC. (US) | 1996-11-12 | — | — | US | claimed |
| EP-0725787-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-08-14 | — | — | EP | claimed |
| WO-1996006853-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-03-07 | — | — | WO | claimed |
| WO-1995024413-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1995-09-14 | — | — | WO | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | TP53 2226/4885TSHR 4585/4885PLA2G4B 2494/4885 |
| US-20100029513-A1 | Methods And Compositions For Generating Mixtures Of Nucleic Acid Molecules | POLM, RNGTT, POLN | TP53 276/4885TSHR 3326/4885PLA2G4B 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.